Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response

CME Activity Information
Release Date:	February 1, 2008
Most Recent Review:	February 1, 2008*
Most Recent Update:	February 1, 2008
Date Credit Expires:	February 1, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by February 1, 2010, in order to receive the credit or participation certificate.

1. Define survival outcomes in women with early-stage breast cancer who achieve pathological complete response following primary systemic chemotherapy.
2. Describe the prognostic value of initial clinical stage in women with breast cancer who achieve pathological complete response following primary systemic chemotherapy.
3. Define survival outcomes in women with inflammatory breast cancer who achieve pathological complete response following primary systemic chemotherapy.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Departments of aBreast Medical Oncology, Quantitative Sciences, Pathology, Radiation Oncology, and Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA; Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates.
Disclosures: The author has indicated no relevant commercial relationships.

Kristine Broglio, M.S.

Credentials: Department of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Shu-Wan Kau, R.N.

Credentials: Department of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

William F. Rabiul Islam, M.D.

Credentials: Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

W. Frasser Symmans, M.D.

Credentials: Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Thomas A. Buchholz, M.D.

Credentials: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author is a principle investigator for preclinical studies funded by a Merck research grant.

Sean E. McGuire, M.D., Ph.D.

Credentials: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Funda Meric-Bernstam, M.D.

Credentials: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Massimo Cristofanilli, M.D.

Credentials: Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Ana M. Gonzalez-Angulo, M.D.

Credentials: Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Telephone: 713-792-2817; Fax: 713-794-4385; E-mail: agonzalez{at}mdanderson.org.
Disclosures: The author has indicated no relevant commercial relationships.

• Take this course